Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1

Author:

Thomas Lawrence J.,Vitale Laura,O'Neill Thomas,Dolnick Ree Y.,Wallace Paul K.,Minderman Hans,Gergel Lauren E.,Forsberg Eric M.,Boyer James M.,Storey James R.,Pilsmaker Catherine D.,Hammond Russell A.,Widger Jenifer,Sundarapandiyan Karuna,Crocker Andrea,Marsh Henry C.,Keler Tibor

Funder

NCI

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy;Journal of Ovarian Research;2024-08-08

2. Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium;JNCI: Journal of the National Cancer Institute;2024-07-04

3. Role of TIM-1 in the development and treatment of tumours;Frontiers in Cell and Developmental Biology;2024-05-20

4. Sensing Dying Cells in Health and Disease;Journal of the American Society of Nephrology;2024-02-14

5. Urinary biomarkers associated with podocyte injury in lupus nephritis;Frontiers in Pharmacology;2024-01-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3